Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...
Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus ...
A drug safety group has delivered a positive analysis for a Sarepta Therapeutics-licensed RNA medicine, with the same study ...
Johnson & Johnson MedTech is expanding its stroke-focused R&D in Ireland, building on previous investments and coming on the ...
VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that has already reeled in a partnership with Biogen. | VC Versant Ventures is ...
Abbott has launched an effort to replace some of its FreeStyle Libre 3 continuous glucose monitors—following reports of hundreds of injuries and seven deaths worldwide—after some sensors | A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback